These findings suggest that LL‐TS may offer a therapeutic approach for reductions in upright heart rate response, alterations in autonomic imbalance, and decreases in NPY levels in individuals with POTS induced by post‐acute COVID‐19. The gene discussed is NPY; the disease is COVID-19.